HVTN503/Phambili Vaccine Trial: The effect of the HIV-1 Clade B-Based Vaccine on Breakthrough Founder Viruses from a Clade C Infected Population

M Logan; T Hertz; PT Edlefsen; A DeCamp; C Magaret; C Rademeyer; M Rolland; BB Larsen; N Frahm; J Marais

HVTN503/Phambili Vaccine Trial: The effect of the HIV-1 Clade B-Based Vaccine on Breakthrough Founder Viruses from a Clade C Infected Population

M Logan
, T Hertz
, PT Edlefsen
, A DeCamp
, C Magaret
, C Rademeyer
, M Rolland
, BB Larsen
, N Frahm
, J Marais

The Shraga Segal Department of Microbiology and Immunology

Research output: Contribution to conference › Abstract › peer-review

Original language	English
Pages	A132-A132
State	Published - 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@conference{69aefa5802834c3c8b1e3aabf97b06cc,

title = "HVTN503/Phambili Vaccine Trial: The effect of the HIV-1 Clade B-Based Vaccine on Breakthrough Founder Viruses from a Clade C Infected Population",

author = "M Logan and T Hertz and PT Edlefsen and A DeCamp and C Magaret and C Rademeyer and M Rolland and BB Larsen and N Frahm and J Marais",

year = "2011",

language = "English",

pages = "A132--A132",

}

TY - CONF

T1 - HVTN503/Phambili Vaccine Trial: The effect of the HIV-1 Clade B-Based Vaccine on Breakthrough Founder Viruses from a Clade C Infected Population

AU - Logan, M

AU - Hertz, T

AU - Edlefsen, PT

AU - DeCamp, A

AU - Magaret, C

AU - Rademeyer, C

AU - Rolland, M

AU - Larsen, BB

AU - Frahm, N

AU - Marais, J

PY - 2011

Y1 - 2011

M3 - Abstract

SP - A132-A132

ER -